Equities Analysts Set Expectations for DWTX FY2025 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Analysts at Zacks Small Cap reduced their FY2025 earnings estimates for shares of Dogwood Therapeutics in a research report issued to clients and investors on Monday, November 10th. Zacks Small Cap analyst D. Bautz now anticipates that the company will post earnings of ($15.31) per share for the year, down from their previous estimate of ($8.71). The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share.

A number of other equities research analysts also recently issued reports on DWTX. HC Wainwright boosted their price target on Dogwood Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, September 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Dogwood Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Dogwood Therapeutics has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Price Performance

Shares of NASDAQ DWTX traded down $0.17 during trading on Thursday, hitting $5.66. 4,768 shares of the company were exchanged, compared to its average volume of 1,473,339. The company has a market cap of $12.96 million, a price-to-earnings ratio of -0.23 and a beta of 1.86. Dogwood Therapeutics has a 1 year low of $1.62 and a 1 year high of $29.28. The firm’s fifty day moving average price is $5.73 and its 200 day moving average price is $5.22.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($8.20) EPS for the quarter, missing the consensus estimate of ($1.23) by ($6.97).

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.